XML 70 R56.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 63,284
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 65,072
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		1,214
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	15 days
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 628
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		5,810
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years 2 months 12 days
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 5,669
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		10,267
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 9,659
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		14,060
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years 8 months 12 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 13,556
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		1,175
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 1,238
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		17,519
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years 10 months 24 days
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 17,192
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		2,697
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years 9 months 18 days
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 4,070
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		7,644
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	5 years 10 months 24 days
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 7,260
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 2,898
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	2 years
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 5,800

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Definition

[Line Items] for Contract With Customer, Asset And Liability [Table]

+ References

No definition available.

+ Details

Name:	xon_ContractWithCustomerAssetAndLiabilityLineItems
Namespace Prefix:	xon_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-04-01
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_ZiopharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_OragenicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_IntrexonEnergyPartnersIILLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_GenopaverLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_FibrocellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_PerseaBioLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_HarvestStartUpEntitiesAggregatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xon_OtherCollaborationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: